1. Home
  2. GLUE vs MEC Comparison

GLUE vs MEC Comparison

Compare GLUE & MEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GLUE
  • MEC
  • Stock Information
  • Founded
  • GLUE 2019
  • MEC 1945
  • Country
  • GLUE United States
  • MEC United States
  • Employees
  • GLUE N/A
  • MEC N/A
  • Industry
  • GLUE Biotechnology: Pharmaceutical Preparations
  • MEC Industrial Specialties
  • Sector
  • GLUE Health Care
  • MEC Industrials
  • Exchange
  • GLUE Nasdaq
  • MEC Nasdaq
  • Market Cap
  • GLUE 351.2M
  • MEC 329.4M
  • IPO Year
  • GLUE 2021
  • MEC 2019
  • Fundamental
  • Price
  • GLUE $4.80
  • MEC $14.60
  • Analyst Decision
  • GLUE Buy
  • MEC Strong Buy
  • Analyst Count
  • GLUE 2
  • MEC 3
  • Target Price
  • GLUE $13.50
  • MEC $21.33
  • AVG Volume (30 Days)
  • GLUE 369.2K
  • MEC 161.8K
  • Earning Date
  • GLUE 08-07-2025
  • MEC 08-05-2025
  • Dividend Yield
  • GLUE N/A
  • MEC N/A
  • EPS Growth
  • GLUE N/A
  • MEC 64.18
  • EPS
  • GLUE 0.29
  • MEC 0.86
  • Revenue
  • GLUE $177,986,000.00
  • MEC $524,606,000.00
  • Revenue This Year
  • GLUE $83.76
  • MEC N/A
  • Revenue Next Year
  • GLUE N/A
  • MEC $17.38
  • P/E Ratio
  • GLUE $16.32
  • MEC $17.07
  • Revenue Growth
  • GLUE 2990.57
  • MEC N/A
  • 52 Week Low
  • GLUE $3.50
  • MEC $11.72
  • 52 Week High
  • GLUE $12.40
  • MEC $23.02
  • Technical
  • Relative Strength Index (RSI)
  • GLUE 51.69
  • MEC 46.47
  • Support Level
  • GLUE $4.54
  • MEC $14.22
  • Resistance Level
  • GLUE $4.93
  • MEC $14.80
  • Average True Range (ATR)
  • GLUE 0.21
  • MEC 0.50
  • MACD
  • GLUE 0.06
  • MEC 0.07
  • Stochastic Oscillator
  • GLUE 81.43
  • MEC 57.65

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

About MEC Mayville Engineering Company Inc.

Mayville Engineering Co Inc is involved in a manufacturing partner providing a full suite of manufacturing solutions from concept to production, including design, prototyping and tooling, fabrication, aluminum extrusion, coating, assembly and aftermarket components. Its customers operate in diverse end markets, including heavy- and medium-duty commercial vehicles, construction, power sports, agriculture, military, and other end markets. Its services comprise stamping, shearing, fiber laser cutting, forming, drilling, tapping, grinding, tube bending, machining, welding, assembly and logistic services.

Share on Social Networks: